Abstract
Cancer is increasingly recognized as “miscommunication” disease, in which inter- and intracellular signals are aberrantly sent and/or received, resulting in the uncontrolled proliferation, survival, and invasiveness of the cancer cell. Indeed, many of the genetic and epigenetic aberrations, which underlie the process of neoplastic transformation and progression, ultimately impinge on the inappropriate activation/inactivation of intracellular signaling pathways. Such signaling cascades usually proceed from the cell surface, where growth factors interact with their specific receptors, to cytoplasmic signaling intermediates, where different signals are integrated and both positive and negative feedback circuitry are in place to ensure signal fidelity and transduction accuracy, to nuclear transcription factors/complexes, which ultimately lead to the transcription/translation of effector genes and proteins involved in specific cellular functions. While the signal may be inappropriately transduced at several, and usually multiple, levels, one interesting feature of aberrant cancer signaling is that cancer cells may become “addicted” to specific signals and hence exquisitely sensitive to their modulation. In this chapter we will describe the signaling process, highlighting the steps at which aberrant signal transduction may turn a normal cell into a cancer cell and the crucial points where aberrant signals can be modulated for therapeutic purposes. Finally, we will briefly touch upon relevant issues surrounding the clinical development of signal transduction inhibitors as anticancer agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ALL:
-
acute lymphocytic leukemia
- AML:
-
acute myeloid leukemia
- AMPK:
-
AMP-activated protein kinase
- ASK1:
-
apoptosis signal kinase 1
- ATP:
-
adenosine triphosphate
- BSC:
-
best supportive care
- Cdk:
-
cyclin-dependent kinase(s)
- CFC:
-
cardio-facio-cutaneous syndrome
- CML:
-
chronic myelogenous leukemia
- 4EBP1:
-
eukaryotic translation initiation factor 4E binding protein 1
- EGFR:
-
epidermal growth factor receptor
- ERK:
-
extracellular-signal-regulated kinase
- FISH:
-
fluorescence in situ hybridization
- FLT3:
-
Fms-like tyrosine kinase 3
- GIST:
-
gastrointestinal stromal tumor(s)
- GSK3:
-
glycogen synthase kinase 3
- Hsp:
-
heat-shock protein
- IRS:
-
Insulin receptor substrate
- JNK:
-
Jun N-terminal kinase
- LAM:
-
Lymphangioleiomyomatosis
- MAPK:
-
mitogen-activated protein kinase
- MEK:
-
MAPK and ERK kinase
- MITF:
-
microphthalmia transcription factor
- MST-2:
-
mammalian sterile 20-like kinase
- mTOR(C):
-
mammalian target of rapamycin (complex)
- NF1:
-
neurofibromatosis 1
- NSCLC:
-
non-small cell lung cancer
- PDGF:
-
platelet-derived growth factor
- PDK1:
-
3-phosphoinositide-dependent protein kinase 1
- PH:
-
pleckstrin homology domain
- PI3K:
-
phosphoinositide 3-kinase
- PI3K:
-
AKT (phosphatidylinositol-3 kinase–AKT)
- PTEN:
-
phosphatase and tensin homolog deleted on chromosome 10
- Raptor:
-
regulatory-associated protein of mTOR
- Ras–Raf–MEK:
-
(mitogen-activated and extracellular-signal-regulated kinase kinase)
- Rheb:
-
Ras homolog enriched in brain
- Rictor:
-
rapamycin-insensitive companion of mTOR
- RNAi:
-
RNA interference
- ROS:
-
reactive oxygen species
- RTK:
-
receptor tyrosine kinase(s)
- S6K1:
-
ribosomal S6 kinase 1
- SCLC:
-
small cell lung cancer
- STAT:
-
signal transducer and activator of transcription
- t-AML:
-
therapy-induced AML
- TGFa:
-
transforming growth factor a
- TK:
-
protein tyrosine kinase(s)
- TKI:
-
tyrosine kinase inhibitor(s)
- TNF:
-
tumor necrosis factor
- TSC:
-
tuberous sclerosis complex
References
Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248
Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347:1593–1603
Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331–341
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Rowley JD (2008) Chromosomal translocations: revisited yet again. Blood 112:2183–2189
Cahill DP, Kinzler KW, Vogelstein B, et al. (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57–M60
Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396:643–649
Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075–3079
Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116
Gronbaek K, Hother C, Jones PA (2007) Epigenetic changes in cancer. APMIS 115:1039–1059
Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054
Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33
Hake SB, Xiao A, Allis CD (2004) Linking the epigenetic “language” of covalent histone modifications to cancer. Br J Cancer 90:761–769
Lachner M, O’Sullivan RJ, Jenuwein T (2003) An epigenetic road map for histone lysine methylation. J Cell Sci 116:2117–2124
Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41–45
Ting AH, McGarvey KM, Baylin SB (2006) The cancer epigenome – components and functional correlates. Genes Dev 20:3215–3231
Allen A (2007) Epigenetic alterations and cancer: new targets for therapy. IDrugs 10:709–712
Gal-Yam EN, Saito Y, Egger G, et al. (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59:267–280
Smith LT, Otterson GA, Plass C (2007) Unraveling the epigenetic code of cancer for therapy. Trends Genet 23:449–456
Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50
Bianco R, Melisi D, Ciardiello F, et al. (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42:290–294
Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365
Parsons JT, Parsons SJ (1993) Protein-tyrosine kinases, oncogenes, and cancer. Important Adv Oncol 3–17
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187
Van Etten RA (2007) Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 204:461–465
Sherbenou DW, Druker BJ (2007) Applying the discovery of the Philadelphia chromosome. J Clin Invest 117:2067–2074
Jones S, Zhang X, Parsons DW, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806
Goutsias J, Lee NH (2007) Computational and experimental approaches for modeling gene regulatory networks. Curr Pharm Des 13:1415–1436
Hornberg JJ, Bruggeman FJ, Westerhoff HV, et al. (2006) Cancer: a systems biology disease. Biosystems 83:81–90
Stransky B, Barrera J, Ohno-Machado L, et al. (2007) Modeling cancer: integration of “omics” information in dynamic systems. J Bioinform Comput Biol 5:977–986
Wang E, Lenferink A, O’Connor-McCourt M (2007) Cancer systems biology: exploring cancer-associated genes on cellular networks. Cell Mol Life Sci 64:1752–1762
Becker J (2004) Signal transduction inhibitors – a work in progress. Nat Biotechnol 22:15–18
Griffith J, Black J, Faerman C, et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13:169–178
Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225
Van Etten RA (2003) c-Abl regulation: a tail of two lipids. Curr Biol 13:R608–R610
Nakao M, Yokota S, Iwai T, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–1918
Sharma SV, Bell DW, Settleman J, et al. (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181
Smith KM, Yacobi R, Van Etten RA (2003) Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 12:27–37
Watanabe D, Ezoe S, Fujimoto M, et al. (2004) Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126:726–735
Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312:1175–1178
Traxler P (2003) Tyrosine kinases as targets in cancer therapy – successes and failures. Expert Opin Ther Targets 7:215–234
Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4:S3–S8
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4:S9–15
Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807
Mendelsohn J (1992) Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 125–131
Rossi A, Bria E, Maione P, et al. (2008) The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. Rev Recent Clin Trials 3:217–227
Comis RL (2005) The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 10:467–470
Siegel-Lakhai WS, Beijnen JH, Schellens JH (2005) Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10:579–589
Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Pao W, Miller V, Zakowski M, et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311
Rosell R, Taron M, Sanchez JJ, et al. (2007) Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol 3:277–283
Sequist LV, Joshi VA, Janne PA, et al. (2007) Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12:90–98
Kobayashi S, Boggon TJ, Dayaram T, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
Pao W, Miller VA, Politi KA, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
Balak MN, Gong Y, Riely GJ, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494–6501
Tokumo M, Toyooka S, Ichihara S, et al. (2006) Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53:117–121
Greulich H, Chen TH, Feng W, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313
Ji H, Li D, Chen L, et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485–495
Jiang J, Greulich H, Janne PA, et al. (2005) Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65:8968–8974
Politi K, Zakowski MF, Fan PD, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496–1510
Sordella R, Bell DW, Haber DA, et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163–1167
Fabian MA, Biggs WH, III, Treiber DK, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329–336
Barber TD, Vogelstein B, Kinzler KW, et al. (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883
Gwak GY, Yoon JH, Shin CM, et al. (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131:649–652
Kwak EL, Jankowski J, Thayer SP, et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283–4287
Lee JW, Soung YH, Kim SY, et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879–2882
Schilder RJ, Sill MW, Chen X, et al. (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539–5548
Bianco R, Shin I, Ritter CA, et al. (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822
Engelman JA, Janne PA, Mermel C, et al. (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102:3788–3793
Avruch J (2007) MAP kinase pathways: the first twenty years. Biochim Biophys Acta 1773:1150–1160
Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37–40
Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49–139
Shaul YD, Seger R (2007) The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773:1213–1226
English JM, Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40–45
Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200–211
McCubrey JA, Steelman LS, Abrams SL, et al. (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279
McCubrey JA, Steelman LS, Chappell WH, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284
Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–947
Wang D, Boerner SA, Winkler JD, et al. (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248–1255
Cobb MH (1999) MAP kinase pathways. Prog Biophys Mol Biol 71:479–500
Garrington TP, Johnson GL (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211–218
Widmann C, Gibson S, Jarpe MB, et al. (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79:143–180
Dhanasekaran N, Premkumar RE (1998) Signaling by dual specificity kinases. Oncogene 17:1447–1455
Kondoh K, Nishida E (2007) Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773:1227–1237
Enslen H, Davis RJ (2001) Regulation of MAP kinases by docking domains. Biol Cell 93:5–14
Sharrocks AD, Yang SH, Galanis A (2000) Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 25:448–453
Volmat V, Pouyssegur J (2001) Spatiotemporal regulation of the p42/p44 MAPK pathway. Biol Cell 93:71–79
Katz M, Amit I, Yarden Y (2007) Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773:1161–1176
Rajalingam K, Schreck R, Rapp UR, et al. (2007) Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773:1177–1195
Galmiche A, Fueller J (2007) RAF kinases and mitochondria. Biochim Biophys Acta 1773:1256–1262
Kyriakis JM (2007) The integration of signaling by multiprotein complexes containing Raf kinases. Biochim Biophys Acta 1773:1238–1247
Leicht DT, Balan V, Kaplun A, et al. (2007) Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773:1196–1212
Crews CM, Alessandrini A, Erikson RL (1992) The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478–480
Seger R, Seger D, Lozeman FJ, et al. (1992) Human T-cell mitogen-activated protein kinase kinases are related to yeast signal transduction kinases. J Biol Chem 267:25628–25631
Boulton TG, Yancopoulos GD, Gregory JS, et al. (1990) An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249:64–67
Chambard JC, Lefloch R, Pouyssegur J, et al. (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773:1299–1310
Whitmarsh AJ (2007) Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim Biophys Acta 1773:1285–1298
Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287–1290
Estep AL, Palmer C, McCormick F, et al. (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2:e1279
Marks JL, Gong Y, Chitale D, et al. (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68:5524–5528
Cowley S, Paterson H, Kemp P, et al. (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841–852
Mansour SJ, Matten WT, Hermann AS, et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966–970
Robinson MJ, Stippec SA, Goldsmith E, et al. (1998) A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 8:1141–1150
McCubrey JA, Milella M, Tafuri A, et al. (2008) Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9:614–630
Milella M, Kornblau SM, Andreeff M (2003) The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7:160–190
Milella M, Precupanu CM, Gregorj C, et al. (2005) Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11:2779–2795
Tortora G, Bianco R, Daniele G, et al. (2007) Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81–100
Chang F, McCubrey JA (2001) P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 20:4354–4364
Malumbres M, Perez dC I, Hernandez MI, et al. (2000) Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 20:2915–2925
Woods D, Parry D, Cherwinski H, et al. (1997) Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17:5598–5611
Kolch W (2001) To be or not to be: a question of B-Raf? Trends Neurosci 24:498–500
Murakami MS, Morrison DK (2001) Raf-1 without MEK? Sci STKE 2001:E30
Zha J, Harada H, Yang E, et al. (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–628
Harada H, Quearry B, Ruiz-Vela A, et al. (2004) Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 101:15313–15317
Ley R, Balmanno K, Hadfield K, et al. (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278:18811–18816
Weston CR, Balmanno K, Chalmers C, et al. (2003) Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22:1281–1293
Luciano F, Jacquel A, Colosetti P, et al. (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22:6785–6793
Deng X, Ruvolo P, Carr B, et al. (2000) Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97:1578–1583
Deng X, Kornblau SM, Ruvolo PP, et al. (2001) Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 30–37
Allan LA, Morrice N, Brady S, et al. (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647–654
Cardone MH, Roy N, Stennicke HR, et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318–1321
O’neill E, Rushworth L, Baccarini M, et al. (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267–2270
Du J, Cai SH, Shi Z, et al. (2004) Binding activity of H-Ras is necessary for in vivo inhibition of ASK1 activity. Cell Res 14:148–154
Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22
Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319
Davies H, Bignell GR, Cox C, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
Yuen ST, Davies H, Chan TL, et al. (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451–6455
Wan PT, Garnett MJ, Roe SM, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867
Zebisch A, Staber PB, Delavar A, et al. (2006) Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 66:3401–3408
Solit DB, Garraway LA, Pratilas CA, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362
Garnett MJ, Rana S, Paterson H, et al. (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20:963–969
Rapp UR, Gotz R, Albert S (2006) BuCy RAFs drive cells into MEK addiction. Cancer Cell 9:9–12
Gregorj C, Ricciardi MR, Petrucci MT, et al. (2007) ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 109:5473–5476
Kornblau SM, Womble M, Qiu YH, et al. (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108:2358–2365
Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657
Katso R, Okkenhaug K, Ahmadi K, et al. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615–675
Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27:5527–5541
Li J, Yen C, Liaw D, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947
Steck PA, Pershouse MA, Jasser SA, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362
Stambolic V, Suzuki A, de la Pompa JL, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29–39
Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22:183–198
Walker SM, Leslie NR, Perera NM, et al. (2004) The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 379:301–307
Alessi DR, James SR, Downes CP, et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261–269
Sarbassov DD, Guertin DA, Ali SM, et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274
Fujita N, Sato S, Katayama K, et al. (2002) Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277:28706–28713
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22
Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729–734
Gao X, Zhang Y, Arrazola P, et al. (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699–704
Tapon N, Ito N, Dickson BJ, et al. (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345–355
Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945
Ma L, Teruya-Feldstein J, Behrendt N, et al. (2005) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19:1779–1786
Manning BD, Logsdon MN, Lipovsky AI, et al. (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773–1778
Hresko RC, Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406–40416
Jacinto E, Loewith R, Schmidt A, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128
Sarbassov DD, Ali SM, Kim DH, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302
Kim DH, Sarbassov DD, Ali SM, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175
Kim DH, Sabatini DM (2004) Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 279:259–270
Sarbassov DD, Ali SM, Sengupta S, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168
Frias MA, Thoreen CC, Jaffe JD, et al. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865–1870
Zeng Z, Sarbassov dD, Samudio IJ, et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509–3512
Cantley LC, Auger KR, Carpenter C, et al. (1991) Oncogenes and signal transduction. Cell 64:281–302
Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94:455–459
Samuels Y, Wang Z, Bardelli A, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
Bachman KE, Argani P, Samuels Y, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772–775
Campbell IG, Russell SE, Choong DY, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681
Saal LH, Holm K, Maurer M, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559
Broderick DK, Di C, Parrett TJ, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64:5048–5050
Lee JW, Soung YH, Kim SY, et al. (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477–1480
Wu G, Mambo E, Guo Z, et al. (2005) Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688–4693
Parsons DW, Wang TL, Samuels Y, et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436:792
Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802–807
Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561–573
Ikenoue T, Kanai F, Hikiba Y, et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562–4567
Wennstrom S, Downward J (1999) Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19:4279–4288
Guan KL, Figueroa C, Brtva TR, et al. (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275:27354–27359
Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741–1744
Karbowniczek M, Cash T, Cheung M, et al. (2004) Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 279:29930–29937
Yee WM, Worley PF (1997) Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol 17:921–933
Carracedo A, Ma L, Teruya-Feldstein J, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065–3074
Beck SE, Carethers JM (2007) BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol Ther 6:1313–1317
Vasudevan KM, Burikhanov R, Goswami A, et al. (2007) Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67:10343–10350
Roux PP, Ballif BA, Anjum R, et al. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101:13489–13494
Ma L, Chen Z, Erdjument-Bromage H, et al. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179–193
Carriere A, Cargnello M, Julien LA, et al. (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18:1269–1277
Meier F, Busch S, Lasithiotakis K, et al. (2007) Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156:1204–1213
Smalley KS, Haass NK, Brafford PA, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136–1144
Grant S (2008) Cotargeting survival signaling pathways in cancer. J Clin Invest 118:3003–3006
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118:3051–3064
Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction – a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457
Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080
Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199–207
D’Cruz CM, Gunther EJ, Boxer RB, et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7:235–239
Moody SE, Sarkisian CJ, Hahn KT, et al. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2:451–461
Moody SE, Perez D, Pan TC, et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197–209
Gunther EJ, Moody SE, Belka GK, et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17:488–501
Kornmann M, Danenberg KD, Arber N, et al. (1999) Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59:3505–3511
Bria E, Cuppone F, Milella M, et al. (2008) Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 8:1963–1971
Bria E, Cuppone F, Fornier M, et al. (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109:231–239
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
McCubrey JA, Steelman LS, Abrams SL, et al. (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22:708–722
Misaghian N, Ligresti G, Steelman LS, et al. (2008) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia
Steelman LS, Abrams SL, Whelan J, et al. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22:686–707
Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
Hughes TP, Kaeda J, Branford S, et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423–1432
Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174
Gorre ME, Mohammed M, Ellwood K, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880
La RP, Corbin AS, Stoffregen EP, et al. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62:7149–7153
Kwak EL, Sordella R, Bell DW, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665–7670
Weinstein IB (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21:857–864
Weinstein IB (2002) Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 297:63–64
Kaelin WG, Jr. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689–698
Mills GB, Lu Y, Kohn EC (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98:10031–10033
Mellinghoff IK, Wang MY, Vivanco I, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024
Sharma SV, Gajowniczek P, Way IP, et al. (2006) A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10:425–435
Mukohara T, Engelman JA, Hanna NH, et al. (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185–1194
Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317–1322
Felsher DW (2008) Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68:3081–3086
Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307–315
Wu CH, van Riggelen J, Yetil A, et al. (2007) Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 104:13028–13033
Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
Moore MJ, Goldstein D, Hamm J, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966
Thatcher N, Chang A, Parikh P, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
Kelly K, Chansky K, Gaspar LE, et al. (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450–2456
Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10:6759–6763
Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
Schneider BP, Wang M, Radovich M, et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678
Vickers AJ, Ballen V, Scher HI (2007) Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing. Clin Cancer Res 13:972–976
Ratain MJ, Karrison TG (2007) Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res 13:781–782
Chan JK, Ueda SM, Sugiyama VE, et al. (2008) Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol 26:1511–1518
Karaman MW, Herrgard S, Treiber DK, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132
Di LA, Moretti E (2008) Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol 26:5011–5013
Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
El-Maraghi RH, Eisenhauer EA (2008) Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 26:1346–1354
Lagakos SW (2006) The challenge of subgroup analyses – reporting without distorting. N Engl J Med 354:1667–1669
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
Freidlin B, Simon R (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 11:7872–7878
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Milella, M., Ciuffreda, L., Bria, E. (2010). Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. In: Reddy, L., Couvreur, P. (eds) Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0507-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0507-9_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0506-2
Online ISBN: 978-1-4419-0507-9
eBook Packages: MedicineMedicine (R0)